Keyphrases
Endothelin Receptor Antagonist
100%
Pulmonary Arterial Hypertension
100%
Sitaxentan
100%
World Health Organization Functional Class
55%
Bosentan
44%
Placebo
33%
Walking Distance
33%
Dyspnea Score
22%
Hypertension Patients
22%
Placebo Groups
11%
Clinical Change
11%
Optimal Dose
11%
Placebo-controlled
11%
Once-daily
11%
Upper Normal Limit
11%
Low Incidence
11%
Exercise Capacity
11%
Treatment Effect
11%
Connective Tissue Disease
11%
6-minute Walk Test (6MWT)
11%
Endothelin-1 (ET-1)
11%
Hepatic Transaminases
11%
Congenital Heart Disease
11%
Functional Hemodynamics
11%
Hepatic Toxicity
11%
Time to Clinical Worsening
11%
Class Time
11%
Class Assessment
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
100%
Sitaxentan
100%
Endothelin A Receptor Antagonist
100%
Placebo
55%
Bosentan
44%
Dyspnea
22%
Connective Tissue Disease
11%
Aminotransferase
11%
Congenital Heart Disease
11%
Endothelin
11%
Hepatic Toxicity
11%